# US 9,517,248 B2 · Adherent cells from adipose or placenta tissues and use thereof in therapy > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 9,517,248 B2 - Document ID: US9517248B2 - Status: Granted - Kind: B2 - Application number: 14/180,039 - Filed: 2014-02-13 - Published: 2014-08-28 - Granted: 2016-12-13 - Earliest claimed: 2007-09-19 - Assignees: Pluristem Ltd. - Applicants: Pluristem Ltd. - Inventors: Moran Meiron; Amir Toren; Rachel Ofir; Zami Aberman; Nirit Drori-Carmi - Web page: https://patentgrep.com/patent/US9517248B2 ## CPC - A61K 35/50: Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells - A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells - A61K 35/35: Fat tissue; Adipocytes; Stromal cells; Connective tissues (adipose-derived stem cells A61K35/28; collagen A61K38/39) - A61K 35/36: Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells (islets of Langerhans A61K35/39) - A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors - A61P 9/00: Drugs for disorders of the cardiovascular system - A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis - A61P 13/12: of the kidneys - A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like - A61P 19/00: Drugs for skeletal disorders - A61P 19/02: for joint disorders, e.g. arthritis, arthrosis - A61P 19/04: for non-specific disorders of the connective tissue - A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease - A61P 19/10: for osteoporosis - A61P 35/00: Antineoplastic agents - A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection - A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract A method of treating ischemia in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of adherent cells of a tissue selected from the group consisting of a placenta and an adipose tissue, thereby treating the ischemia in the subject. A method of treating a medical condition requiring connective tissue regeneration and/or repair is also disclosed. ## Claims ### Claim 1 A method of treating a wound in a subject in need thereof, comprising systemically administering to the subject a therapeutically effective amount of undifferentiated placenta-derived adherent stromal cells in a liquid suspension, wherein the adherent stromal cells do not express CD34, thereby treating the wound. ### Claim 2 (depends on 1) The method of claim 1, wherein at least 10% of said cells are at a proliferative phase. ### Claim 3 (depends on 1) The method of claim 1, wherein the wound is a wound to the skin. ### Claim 4 (depends on 1) The method of claim 1, wherein said cells have been propagated in three-dimensional (3D) culturing conditions. ### Claim 5 (depends on 4) The method of claim 4, wherein said three-dimensional (3D) culturing conditions comprise a 3D bioreactor. ### Claim 6 (depends on 4) The method of claim 4, wherein said three-dimensional (3D) culturing conditions are effected under perfusion. ### Claim 7 (depends on 4) The method of claim 4, wherein said three-dimensional (3D) culturing conditions comprise an adherent material selected from the group consisting of a polystyrene, a polyester, and a polypropylene. ### Claim 8 (depends on 1) The method of claim 1, wherein said cells have been cultured for at least 3 days. ### Claim 9 (depends on 1) The method of claim 1, wherein said cells have been cultured until at least 10% of said cells are proliferating. ### Claim 10 (depends on 4) The method of claim 4, wherein said cells express a marker selected from the group consisting of CD73, CD90, CD29 and CD105. ### Claim 11 (depends on 4) The method of claim 4, wherein said cells do not express a marker selected from the group consisting of CD3, CD4, CD45, CD80, HLA-DR, CD11b, CD14, CD19 and CD79. ### Claim 12 (depends on 6) The method of claim 6, wherein said perfusion rate is adjusted in order to maintain a constant glucose concentration in the culture medium. ### Claim 13 (depends on 12) The method of claim 12, wherein said constant glucose concentration is about 550 mg/L. ### Claim 14 (depends on 1) The method of claim 1, wherein said cells have been propagated in two-dimensional (2D) culturing conditions. ### Claim 15 (depends on 14) The method of claim 14, wherein said cells express a marker selected from the group consisting of CD90, CD105, CD73 and CD29. ### Claim 16 (depends on 1) The method of claim 1, wherein treating the wound comprises treating delayed wound healing. ### Claim 17 (depends on 16) The method of claim 16, wherein the wound is an ulcer. ### Claim 18 (depends on 17) The method of claim 17, wherein the ulcer wound is to the skin. ### Claim 19 (depends on 3) The method of claim 3, wherein the wound to the skin is an ulcer. ### Claim 20 (depends on 1) The method of claim 1, wherein the undifferentiated placenta-derived adherent stromal cells are non-autologous to the subject. ### Claim 21 A method of preparing cells for treating a wound in a subject in need thereof, the method comprising expanding placenta-derived adherent stromal cells in culture, wherein when the culture-expanded placenta-derived adherent stromal cells are subsequently systemically administered in a liquid suspension to a subject in a therapeutically effective amount they treat a wound in the subject. ### Claim 22 (depends on 21) The method of claim 21, wherein the culture is a 3D culture. ### Claim 23 (depends on 22) The method of claim 22, wherein said placenta-derived adherent stromal cells are non-autologous to the subject. ### Claim 24 A method of preparing cells for treating a wound in a subject in need thereof, the method comprising expanding non-autologous placenta-derived adherent stromal cells in three-dimensional culture, wherein when the culture-expanded placenta-derived adherent stromal cells are subsequently systemically administered in a liquid suspension to the subject in a therapeutically effective amount they treat a wound in the subject.